Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Argus Health
Cipla
Chinese Patent Office
McKinsey
Boehringer Ingelheim
Dow
Mallinckrodt
Express Scripts
Fish and Richardson

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,530,694

« Back to Dashboard

Which drugs does patent 8,530,694 protect, and when does it expire?

Patent 8,530,694 protects NINLARO and is included in one NDA.

This patent has fifty patent family members in thirty-three countries.
Summary for Patent: 8,530,694
Title:Proteasome inhibitors
Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Inventor(s): Olhava; Edward J. (Newton, MA), Danca; Mihaela Diana (Mendham, NJ)
Assignee: Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/209,511
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 8,530,694

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-001 Nov 20, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA ➤ Sign Up
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-002 Nov 20, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA ➤ Sign Up
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-003 Nov 20, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,530,694

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,442,830 Proteasome inhibitors ➤ Sign Up
8,772,536 Proteasome inhibitors ➤ Sign Up
8,871,745 Proteasome inhibitors ➤ Sign Up
7,687,662 Proteasome inhibitors ➤ Sign Up
8,003,819 Proteasome inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,530,694

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan 201425321 ➤ Sign Up
Taiwan I511972 ➤ Sign Up
Taiwan 201425320 ➤ Sign Up
Taiwan I440641 ➤ Sign Up
Taiwan 200914460 ➤ Sign Up
Tunisia 2010000060 ➤ Sign Up
Slovenia 2178888 ➤ Sign Up
Singapore 10201508712Q ➤ Sign Up
Serbia 52435 ➤ Sign Up
Portugal 2178888 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Fuji
Citi
Covington
Chubb
Julphar
US Department of Justice
Farmers Insurance
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot